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The orexigenic peptide hormone ghrelin is synthesized in the stomach and its receptor
growth hormone secretagogue receptor (GHSR1a) is expressed mainly in the central ner-
vous system (CNS). In this review, we confine our discussion to the physiological role of
GHSR1a in the brain. Paradoxically, despite broad expression of GHSR1a in the CNS, other
than trace amounts in the hypothalamus, ghrelin is undetectable in the brain. In our efforts
to elucidate the function of the ligand-free ghrelin receptor (apo-GHSR1a), we identified
subsets of neurons that co-express GHSR1a and dopamine receptors. In this review, we
focus on interactions between apo-GHSR1a and dopamine-2 receptor (DRD2) and forma-
tion of GHSR1a:DRD2 heteromers in hypothalamic neurons that regulate appetite, and
discuss implications for the treatment of Prader–Willi syndrome (PWS). GHSR1a antago-
nists of distinct chemical structures, a quinazolinone and a triazole, respectively, enhance
and inhibit dopamine signaling through GHSR1a:DRD2 heteromers by an allosteric mecha-
nism.This finding illustrates a potential strategy for designing the next generation of drugs
for treating eating disorders as well as psychiatric disorders caused by abnormal dopamine
signaling. Treatment with a GHSR1a antagonist that enhances dopamine/DRD2 activity in
GHSR1a:DRD2 expressing hypothalamic neurons has the potential to inhibit the uncon-
trollable hyperphagia associated with PWS. DRD2 antagonists are prescribed for treating
schizophrenia, but these block dopamine signaling in all DRD2 expressing neurons and are
associated with adverse side effects, including enhanced appetite and excessive weight
gain. A GHSR1a antagonist of structural class that allosterically blocks dopamine/DRD2
action in GHSR1a:DRD2 expressing neurons would have no effect on neurons expressing
DRD2 alone; therefore, the side effects of DRD2 antagonists would potentially be reduced
thereby enhancing patient compliance.
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INTRODUCTION
The orexigenic hormone ghrelin is produced in stomach and
influences feeding behavior, metabolism, pulsatile growth hor-
mone (GH) release, and immune function (1–4). Ghrelin’s action
is regulated by the GH secretagogue receptor (GHSR1a, aka
the ghrelin receptor) that was originally identified by reverse
pharmacology using a small molecule, MK-0677, developed to
rejuvenate the GH/insulin-like growth factor axis in elderly sub-
jects (5, 6). GHSR1a belongs to the Class A G-protein coupled
receptor (GPCR) family. In isolation, under defined conditions,
GHSR1a couples to Gαq resulting in activation of phospho-
lipase C (PLC), inositol trisphosphate (IP3), and mobilization
of [Ca2+]i (7).
The precise physiological function of ghrelin remains to be
defined. Traditionally ghrelin was believed to control appetite and
facilitate excessive weight gain in response to a high-fat diet, but
recent findings question these conclusions. Studies in congenic
C57BL/6J ghrelin knockout (KO) and ghsr KO mice showed food
intake is independent of ghrelin signaling, and that the absence
of ghrelin fails to protect mice from diet-induced obesity (8–10).
Indeed, recent results in transgenic mice where ghrelin producing
cells were selectively ablated confirm these findings (11). Acute
stimulation of food intake in ghrelin-cell ablated mice requires
doses of exogenous ghrelin that produce plasma ghrelin concen-
trations many-fold higher than the endogenous concentrations
found in wildtype mice, suggesting endogenous ghrelin is not a
critical regulator of food intake. With prolonged calorie restric-
tion ghrelin-cell ablated mice exhibit profound hypoglycemia (11).
Similarly, profound hypoglycemia was reported by the same group
in calorie-restricted ghrelin-deficient mice generated by ablat-
ing medium chain fatty acid acyl-transferase that is essential for
converting the inactive 28-aminoacid ghrelin peptide into its bio-
logically active form (12). Injection of ghrelin or GH rescued
the hypoglycemia. Based on the results from these two trans-
genic mouse models, the authors concluded that ghrelin’s major
metabolic role is to regulate blood glucose under conditions of
famine.
GHSR1a is expressed broadly in the brain and localized
mainly in the hippocampal structures, hypothalamus, midbrain,
cortex, and amygdala (13). These findings led us to investi-
gate possible interactions of GHSR1a with dopamine recep-
tors. By employing Ghsr-IRES-tau-GFP mice, we showed that
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subsets of neurons in the midbrain and hippocampus co-
express GHSR1a and dopamine receptor-1 (DRD1) (14), and
in the hypothalamus subsets co-express GHSR1a and dopamine
receptor-2 (DRD2) (15). In vitro studies illustrated the forma-
tion of GHSR1a:DRD1 heteromers, and treatment with ghre-
lin and dopamine in combination augmented cAMP accumu-
lation (14). Again, using Ghsr-IRES-tau-GFP mice, we identi-
fied subsets of hypothalamic neurons that co-express GHSR1a
and dopamine-2 receptor (DRD2) (15). DRD2 signaling influ-
ences feeding frequency and volume, and mutations in DRD2
are associated with human obesity (16–20). In this review, we
describe the co-expression of GHSR1a with dopamine recep-
tors in neurons of the CNS, the dependence on GHSR1a for
dopamine/DRD2 suppression of appetite and implications for
the uncontrollable hyperphagia associated with Prader–Willi
syndrome (PWS).
GHRELIN ACTIVATION OF HYPOTHALAMIC NEURONS
ENHANCES DOPAMINE RELEASE FROMMIDBRAIN
DOPAMINERGIC NEURONS
Pharmacological doses of ghrelin activate extra-hypothalamic
neurons implicating a role for ghrelin in memory, addiction,
depression, and neuroprotection (21–27). Indeed, ghsr−/− mice
exhibit impaired contextual memory (28). In addition, improve-
ments in spatial memory induced by exogenous ghrelin are
inhibited by a dopamine-1 receptor (DRD1) antagonist (29).
Ghrelin also augments cocaine-induced locomotor activity and
the rewarding effects of alcohol, consistent with effects on
dopamine signaling (30, 31). Although ghrelin administration
induces dopamine release (30), there is no evidence that ghre-
lin has direct access to midbrain dopaminergic neurons (32).
Exogenously applied ghrelin activates c-Fos expression in the
arcuate nucleus, paraventricular nucleus (PVN), and lateral hypo-
thalamus (LH), but not in GHSR1a expressing neurons of the
midbrain or hippocampus (33, 34). Tracing studies with inac-
tivated rabies virus show that neurons in the ventral tegmental
area (VTA) and pars compacta of the substantia nigra (SNpc)
receive projections from the PVN and LH (33–35). Furthermore,
infusion of ghrelin into the LH, but not in the VTA, stimu-
lates orexin release, which activates orexin receptors on VTA
neurons causing release of dopamine (36). Neuroanatomy, neu-
ropharmacology, and cell biology studies indicate VTA dopamin-
ergic neurons innervate the hippocampus (37–41). These collec-
tive observations are consistent with exogenous ghrelin induc-
ing hippocampal plasticity indirectly by first activating neurons
in the LH and PVN that in turn enhance dopamine release
from the VTA resulting in activation of hippocampal neurons.
However, these results obtained using pharmacological doses
of ghrelin cannot simply be extrapolated to predict the phys-
iological role of endogenous ghrelin. A recent series of stud-
ies in mice and sheep indicate that other than trace amounts
in the hypothalamus, endogenous ghrelin is not present in the
CNS (42–45). This is remarkable given the broad distribution of
GHSR1a in the brain and underlines a potential role for GHSR1a
independent of ghrelin, which led us to speculate that apo-
GHSR1a regulates neuronal function through protein–protein
interactions.
GHSR1a AND DRD2 ARE CO-EXPRESSED IN HYPOTHALAMIC
NEURONS RESULTING IN MODIFICATION OF CANONICAL
DOPAMINE SIGNALING
Since endogenous ghrelin is undetectable in the brain, we
addressed the question of what biological role un-liganded
GHSR1a (apo-GHSR1a) might play by focusing on the function
of hypothalamic neurons that co-express GHSR1a and DRD2. To
determine the impact of expression of apo-GHSR1a on DRD2
signaling, we initially used HEK293 cells where we could control
the relative expression levels of the two receptors and investigate
signal transduction pathways. Dopamine activation of DRD2 in
HEK293 cells results in canonical DRD2 coupling to Gαi/o and
suppression of intracellular cAMP accumulation without mobi-
lization of intracellular Ca2+ ([Ca2+]i) (46). However, when
GHSR1a is expressed with DRD2, treatment with dopamine, or the
DRD2 agonist quinpirole results in [Ca2+]i mobilization. When
DRD2 is expressed with the motilin receptor, which is closely
related to GHSR1a and is also coupled to Gαq, neither dopamine
nor quinpirole treatment mobilizes [Ca2+]i, illustrating the sig-
nificance of specific interactions between GHSR1a and DRD2.
When GHSR1a is co-expressed with DRD2, dopamine-induced
[Ca2+]i release is blocked by: pertussis toxin, Gβγ antagonists,
PLC inhibitor, thapsigargin, and IP3 receptor blocker. We con-
clude that dopamine activation causes liberation of Gβγ subunits
from Gαi/o, activation of PLC, IP3 mobilization, and release of
[Ca2+]i (Figure 1). Importantly, this mechanism is activated in
the complete absence of ghrelin. A mechanism involving down-
stream cross-talk between GHSR1a and DRD2 caused by GHSR1a
basal activity was ruled out. Blocking GHSR1a basal activity with
Gαq siRNA or GHSR1a point mutants that lack constitutive activ-
ity failed to inhibit dopamine-induced [Ca2+]i release. The lack
of cross-talk between the two receptors supports the hypothesis
that GHSR1a and DRD2 co-expression results in non-canonical
DRD2 signal transduction that is dependent on allosteric interac-
tions between GHSR1a and DRD2 protomers. These results were
recapitulated in DRD2 expressing SH-SY5Y neuroblastoma cells
engineered to stably express GHSR1a, and in primary cultures
of hypothalamic neurons (15), confirming that non-canonical
DRD2 signaling is dependent upon interactions between GHSR1a
and DRD2.
DRD2 AGONIST SUPPRESSION OF FEEDING BEHAVIOR IS
DEPENDENT ON GHSR1a AND FORMATION OF GHSR1a:DRD2
HETEROMERS IN HYPOTHALAMIC NEURONS
The change in canonical to non-canonical DRD2 signal trans-
duction when GHSR1a is co-expressed with DRD2 implicates
allosteric interactions between GHSR1a and DRD2 as a result
of GHSR1a:DRD2 heteromer formation. It is well documented,
based mainly on in vitro experiments, that GPCRs form homo-
mers and heteromers, and that in heteromers one protomer in
the complex allosterically modifies signaling of the other (47,
48). To test if modification of signal transduction is a conse-
quence of a physical interaction between GHSR1a and DRD2,
time resolved fluorescence resonance energy transfer (Tr-FRET)
experiments were conducted in HEK293 cells (49, 50). The high
sensitivity of Tr-FRET where SNAP- or CLIP-tags are introduced
at the N-terminus of GHSR1a and DRD2 allowed monitoring
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of GHSR1a:GHSR1a and GHSR1a:DRD2 heteromer formation at
physiological concentrations on the surface of living cells (15).
When SNAP-GHSR1a is expressed in the presence of untagged
DRD2 at a 1:1 ratio the Tr-FRET signal generated by GHSR1a
homomers was reduced by ~50%, consistent with formation of
GHSR1a:DRD2 heteromers. As further confirmation of direct
interactions and heteromer formation, Tr-FRET assays were per-
formed using SNAP-GHSR1a and CLIP-DRD2 in a receptor titra-
tion assay. High Tr-FRET signals were detected over a wide range
FIGURE 1 | Dopamine-induced [Ca2+]i mobilization via GHSR1a:DRD2
heteromers. Dopamine activation of GHSR1a:DRD2 causes release of Ca2+
from intracellular stores by Gβγ dependent PLC activation and mobilization
of IP3.
of receptor expression, confirming GHSR1a:DRD2 heteromeriza-
tion. To test if formation of heteromers was functionally relevant,
Tr-FRET results were compared to the magnitude of dopamine-
induced [Ca2+]i mobilization at various ratios of GHSR1a to
DRD2. Dopamine-induced [Ca2+]i release correlated with the
concentration of GHSR1a:DRD2 heteromers. Indeed, in sup-
port of an allosteric mechanism, the GHSR1a neutral antago-
nist, JMV2959, inhibited dopamine-induced [Ca2+]i mobilization
without disrupting heteromer formation; similarly, a DRD2 antag-
onist attenuated ghrelin signaling (15). Collectively, these data
show that in cell lines modification of canonical DRD2 signaling
is dependent on formation of GHSR1a:DRD2 heteromers (15).
To test if GHSR1a:DRD2 heteromer formation has physio-
logical relevance, we sought evidence for the presence of the
heteromers in native brain tissue. We applied confocal FRET
microscopy on mouse hypothalamic neurons using a fluorescently
labeled ghrelin analog to visualize GHSR1a, and a fluorescently
tagged DRD2 monoclonal antibody to localize DRD2. In hypo-
thalamic neurons from Ghsr+/+ mice, confocal FRET microscopy
analysis shows GHSR1a and DRD2 in close proximity within
5 nm, consistent with heteromer formation (Figure 2). In striatal
neurons of Ghsr+/+ mice, the confocal FRET signal is very weak
indicating the absence of heteromers in the striatum. In hypo-
thalamic neurons of Ghsr−/− mice, a confocal FRET signal is
not detected confirming the specificity of imaging GHSR1a:DRD2
heteromers in Ghsr ++mice (15).
The physiological importance of GHSR1a:DRD2 interactions
was tested by monitoring food intake of fasted Ghsr+/+ and
Ghsr−/− mice following treatment with the selective DRD2 ago-
nist cabergoline. In Ghsr+/+ mice, food intake was markedly
inhibited by cabergoline compared to vehicle treated animals, but
Ghsr−/− mice were refractory to cabergoline-induced anorexia;
hence, the anorexigenic activity of DRD2 is dependent upon
GHSR1a. To test if endogenous ghrelin played a role, food intake
was compared in Ghrelin+/+ and Ghrelin−/− mice treated with
cabergoline. Cabergoline inhibited food intake in both genotypes,
FIGURE 2 | In hypothalamic neurons GHSR1a and DRD2 form
heteromers. Hypothalamic brain slices from Ghsr+ /+ mice were used to
identify GHSR1a:DRD2 heteromers. Confocal FRET microscopy show that
GHSR1a [identified using red fluorescent ghrelin (Cy5)] and DRD2 [in green,
identified by immunofluorescent DRD2 monoclonal antibody (Cy3)] are in
close proximity at a distance of 5–6 nm and FRET intensity 0.4–0.6 (15).
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FIGURE 3 | Anorexigenic effect of a DRD2 agonist is mediated
by GHSR1a:DRD2 heteromers. Treatment of fasted Ghsr+ /+ mice
with the DRD2 agonist cabergoline inhibits food intake. Ghsr−/−
mice, and Ghsr+ /+ mice treated with the ghrelin receptor neutral
antagonist, JMV2959, are refractory to the anorexigenic effects of
cabergoline; hence, inhibition of food intake by cabergoline is
dependent upon allosteric interactions between GHSR1a and
DRD2.
showing that the anorexigenic activity of the DRD2 agonist is
dependent on GHSR1a but not on ghrelin. Having shown in
cells co-expressing GHSR1a and DRD2 that the GHSR1a neutral
antagonist, JMV2959, inhibits dopamine-induced [Ca2+]i mobi-
lization, mice were pretreated with JMV2959 before cabergoline
injection. JMV2959 inhibited the anorexigenic effect of cabergo-
line inGhsr+/+mice, but not inGhsr−/−mice; thus the antagonis-
tic action of JMV2959 on DRD2 activity is dependent on GHSR1a.
These data illustrate that allosteric interactions between GHSR1a
and DRD2 as a consequence of heteromer formation are physio-
logically relevant mediators of feeding behavior (Figure 3) (15).
Our results support the concept that heteromerization of
GPCRs is an important mechanism for regulating GPCR function.
Many GPCRs function as oligomeric complexes, where recep-
tors physically interact to form homo- or heteromers. These
protein–protein interactions stabilize specific conformations of
GPCRs to activate specific down-stream effectors and signal-
ing pathways (51–54). For example, ghrelin inhibition of insulin
release from pancreatic beta-cells is mediated by GHSR1a cou-
pling to Gαi rather than canonical coupling through Gαq (55);
this modification in G-protein coupling is a consequence of for-
mation of heteromers formed between GHSR1a and somato-
statin receptor-5 (56). Heterodimers formed between GHSR1a and
melanocortin-3 receptor has also been reported, and a combina-
tion of in situ hypridization and immunohistochemistry indicated
co-localization of the receptors in hypothalamic neurons (57).
Examples of dimerization of GPCRs in vitro are well docu-
mented, but the physiological relevance is repeatedly questioned
because of the paucity of data illustrating dimerization in native
tissues. However, we show by applying FRET confocal microscopy
the presence of GHSR1a:DRD2 heteromers in native hypothala-
mic neurons and further that inhibition of food intake by a DRD2
agonist is dependent on GHSR1a. Formation of the heteromeric
complex results in non-canonical signaling dependent on Gβγ
activation of PLC and mobilization of [Ca2+]i. This occurs in the
absence of ghrelin, showing apo-GHSR1a is capable of allosteri-
cally modifying DRD2 signaling. The allosteric interaction within
the GHSR1a:DRD2 heteromer is altered by the presence of a neu-
tral GHSR1a antagonist (15); hence, the conformation of one
protomer influences the signaling properties of the other. These
findings demonstrate an important role for apo-GHSR1a in the
brain and resolve the paradox that GHSR1a is expressed in brain
areas not accessible to peripherally produced ghrelin, and where
there is no evidence of ghrelin production.
IMPLICATIONS OF GHSR1:DRD2 HETEROMERS IN OBSESSIVE
EATING ASSOCIATED WITH PRADER–WILLI SYNDROME
Prader–Willi syndrome is a genetic disorder occurring in approx-
imately 1 in 10,000 births and is associated with parent of origin
imprinting. In normal subjects, maternal 15q11.2 is imprinted, but
the paternal chromosome has a working copy of 15q11.2. Patients
with PWS lack a working copy because of paternal deletion (70%
of cases), maternal uniparental disomy (mUPD, 25% of cases),
or imprinting errors in the imprinting center (IC, 5% of cases)
(58). The deletion or lack of expression of 15q11.2 on the paternal
chromosome results in a complex multi-systemic disorder. The
phenotype includes short stature, low muscle tone, uncontrollable
appetite, incomplete sexual development, and impaired cognition.
The behavioral characteristics fall into the spectrum of autism
spectrum disorders. In narrowing down the DNA region respon-
sible for PWS, it was found that individuals with paternal deletion
of the SNORD116 gene cluster had all the major characteristic
features of PWS (59). This locus encompasses a long non-coding
RNA transcript that is processed into multiple small nuclear RNAs,
as well as spliced exons of host gene 116G (60). The expression
of Snord116 in mice becomes progressively more prominent in
the arcuate nucleus, PVN, and ventromedial nucleus of the hypo-
thalamus as the mice mature (61); these particular areas express
GHSR1a and are involved in regulation of appetite mediated by
DRD2.
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While GH replacement is frequently used to treat impaired
growth and hypotonia associated with PWS, the most distinguish-
ing feature, for which there is no medical therapy, is the involuntary
and uncontrollable chronic feeling of hunger, combined with a
slow metabolism that leads to excessive eating and life-threatening
obesity (62–64). The major theory proposed for explaining the
insatiable appetite and excessive weight gain associated with PWS
is elevated circulating levels of the orexigenic hormone ghrelin in
the blood (65–67). Despite this, the direct approach of treating
PWS patients with a GHSR1a antagonist, to our knowledge, has
not been tested; this is likely because early clinical studies where
GHSR1a antagonists were tested as antiobesity agents in normal
subjects proved disappointing. The age-dependent (7 months to
5 years) transition to hyperphagia in PWS does not correlate with
a change in ghrelin levels (68). However, as PWS children progress
into adulthood hyperphagia becomes more severe; notably, the
postprandial decrease in ghrelin observed in normal subjects is
absent (69). Indeed, this is a most important distinction between
normal and PWS adults. The postprandial nadir in endogenous
ghrelin observed in normal subjects provides a mechanism for
GHSR1a re-sensitization, and a satiety signal to tell the brain – stop
eating! Indeed, the overall phenotype of PWS can be interpreted as
impaired GHSR1a re-sensitization and as consequence low levels
of active GHSR1a.
Prader–Willi syndrome patients present with high ghrelin and
low GH levels; however, the anterior pituitary gland appears
structurally normal and produces GH, suggesting impaired
hypothalamic-pituitary signaling. Since GHSR1a agonists, includ-
ing ghrelin, stimulate GH release, a possible explanation, other
than GHSR1a desensitization, is that GHSR expression is atten-
uated. Expression of GHSR is positively regulated by thyroid
hormone and estradiol, and negatively by cortisol (70). Indeed,
hypothyroidism, hypogonadism, and elevated cortisol are all
associated with PWS (71). Although not assessed quantitatively,
GHSR1a expression appears normal in brains from deceased PWS
patients (72). Nevertheless, compared to normal subjects, PWS
patients elicit attenuated GH release in response to a GHSR1a ago-
nist (73). High plasma concentrations of ghrelin should result in
hyperglycemia and insulin resistance, but these metabolic changes
are not consistently observed in PWS (73, 74). Lowering ghrelin
levels by administering somatostatin or octreotide had no effect on
appetite, weight gain, or behavior in PWS subjects (75–77). How-
ever, this does not preclude a role for ghrelin, because these com-
pounds also suppress secretion of gastrointestinal anorexigenic
hormones (76).
A recent report on the Snord116±mouse model of PWS showed
that different inhibitors of GHSR1a failed to inhibit food intake
(78) and that the involvement of some new pathway is linked to
changes in feeding and psychiatric behavior (79). The authors con-
cluded that ghrelin signaling is not involved in PWS and perhaps
the elevated plasma ghrelin concentration is playing a compen-
satory role in PWS subjects. These findings support our suggestion
that elevated endogenous ghrelin results in GHSR1a desensiti-
zation and lower levels of active GHSR1a. Low GHSR1a levels
on the plasma membrane of hypothalamic neurons would pre-
dictably cause hyperphagia because as described above the appetite
suppressing effect of DRD2 agonists is dependent on molecular
interactions with apo-GHSR1a and DRD2 (15). Indeed, ghsr−/−
mice are completely resistant to the anorexigenic effect of the
DRD2 agonist cabergoline. Down-stream, cabergoline increases
expression and signaling of brain-derived neurotrophic factor
(BDNF). BDNF is one of the most important suppressors of food
intake, and BDNF is low in PWS (80, 81).
Endogenous dopamine signaling via DRD2 inhibits excessive
food intake and is dependent upon apo-GHSR1a and formation
of GHSR1a:DRD2 heteromers. Formation of heteromers results
in non-canonical DRD2 signal transduction and suppression of
food intake. We suggest that persistently elevated circulating ghre-
lin in PWS reduces accumulation of GHSR1a on the plasma
membrane of hypothalamic neurons. Low concentrations of
GHSR1a contribute to hyperphagia by lowering the concentration
of GHSR1a:DRD2, thereby attenuating satiety signals regulated
by dopamine. The feasibility of targeting heterodimers formed
between GHSR1a and DRD2 to modify non-canonical dopamine
signaling was illustrated by us previously (15). This finding pro-
vides an approach to suppress or augment dopamine signaling
selectively in neurons that express GHSR1a:DRD2 through an
allosteric mechanism. Indeed, we have identified GHSR1a antag-
onists belonging to distinct structural classes, quinazolinones and
triazoles that respectively enhance and inhibit DRD2 signaling
through GHSR1a:DRD2 heteromers. Since these heteromers are
found in a hypothalamic regions involved in development of PWS,
GHSR1a antagonists that enhance DRD2 signaling are poten-
tial candidates for therapeutic intervention to suppress appetite.
Targeting dopamine signaling in GHSR1a:DRD2 expressing neu-
rons with GHSR1a antagonists provides the opportunity to design
drugs that selectively target neurons co-expressing GHSR1a and
DRD2 without affecting neurons expressing DRD2 alone.
SUMMARY
In subsets of hypothalamic neurons that co-express GHSR1a and
DRD2, GHSR1a:DRD2 heteromers are formed. Formation of
these heteromers results in allosteric modification of the confor-
mation of DRD2, thereby causing non-canonical signal transduc-
tion in response to dopamine. In contrast to canonical DRD2 sig-
nal transduction that involves suppression of cAMP accumulation,
the non-canonical pathway results in Gβγγ subunit-dependent
activation of PLC and mobilization of [Ca2+]i. The physiological
relevance of GHSR1a:DRD2 heteromers is illustrated by experi-
ments inGhsr+/+,Ghsr−/−, andGhrelin−/−mice. DRD2 agonism
produces anorexia in Ghsr+/+ and Ghrelin−/− mice, but not in
Ghsr−/− mice. Hence, the anorexigenic effects of DRD2 agonists
are dependent on GHSR1a, but not ghrelin. Further,Ghsr+/+mice
treated with a neutral GHSR1a antagonist (the triazole, JMV2959)
are resistant to DRD2 agonist-induced anorexia. Hence, phar-
macological intervention with a GHSR1a antagonist according
to structure, triazole vs. quinazolinone will respectively alloster-
ically block or enhance dopamine signaling in neurons expressing
GHSR1a:DRD2 heteromers without affecting signaling in neu-
rons expressing DRD2 alone. These results show the potential of
developing drugs that selectively act on subsets of neurons that
express GHSR1a:DRD2 heteromers for treating obsessive eating
disorders such as in PWS and for psychiatric disorders associated
with irregularities in dopamine signaling.
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